Cargando…
Next generation of biologics for the treatment of Crohn’s disease: an evidence-based review on ustekinumab
The limited efficacy of the currently available medical therapies in a proportion of patients with Crohn’s disease has led to the research and development of molecules that can block new inflammatory pathways. Ustekinumab is a fully human IgG1 monoclonal antibody which targets the common p40 subunit...
Autores principales: | Jauregui-Amezaga, Aranzazu, Somers, Michael, De Schepper, Heiko, Macken, Elisabeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697448/ https://www.ncbi.nlm.nih.gov/pubmed/29180886 http://dx.doi.org/10.2147/CEG.S110546 |
Ejemplares similares
-
Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017) -
Successful Treatment of Oral Crohn’s Disease by Ustekinumab
por: Jukema, Jelmer B, et al.
Publicado: (2020) -
Ustekinumab for Successful Treatment of Refractory Esophageal Crohn’s Disease
por: Barkin, Jodie A., et al.
Publicado: (2016) -
Clinical utility of ustekinumab in Crohn’s disease
por: Kotze, Paulo Gustavo, et al.
Publicado: (2018) -
Hypersensitivity to IV Ustekinumab but Tolerance to Subcutaneous Ustekinumab in a Patient With Crohn's Disease
por: Krugliak Cleveland, Noa, et al.
Publicado: (2020)